title: Comparison between effects of myo-inositol and D-chiro-inositol on ovarian function and metabolic factors in women with PCOS.
abstract: Myo-inositol and D-chiro-inositol are capable of improving the ovarian function and metabolism of polycystic ovary syndrome (PCOS) patients. The aim of this work is to compare the effects of myo-inositol and D-chiro-inositol in PCOS. We enrolled 50 patients, with homogeneous bio-physical features, affected by PCOS and menstrual irregularities, and we randomly divided them into two groups: 25 were treated with 4 g of myo-inositol/die plus 400 mcg of folic acid/die orally for six months, 25 with 1 g of D-chiro-inositol/die plus 400 mcg of folic acid/die orally for six months. We analyzed in both groups pre-treatment and post-treatment BMI, systolic and diastolic blood pressure, Ferriman-Gallwey score, Cremoncini score, serum LH, LH/FSH ratio, total and free testosterone, dehydroepiandrosterone sulfate (DHEA-S), Δ-4-androstenedione, SHBG, prolactin, glucose/immunoreactive insulin (IRI) ratio, homeostatic model assessment (HOMA) index, and the resumption of regular menstrual cycles. Both the isoforms of inositol were effective in improving ovarian function and metabolism in patients with PCOS, although myo-inositol showed the most marked effect on the metabolic profile, whereas D-chiro-inositol reduced hyperandrogenism better.
authors.affiliation: Department of Pediatric, Gynecological, Microbiological and Biomedical Sciences, University of Messina , Messina , Italy and.
authors.forename: Alfonsa
authors.initials: A
authors.lastname: Pizzo
authors.forename: Antonio Simone
authors.initials: AS
authors.lastname: Laganà
authors.forename: Luisa
authors.initials: L
authors.lastname: Barbaro
mesh_terms: D000293:Adolescent; D000328:Adult; D000568:Amenorrhea / Q000209:etiology / Q000517:prevention & control; D019587:Dietary Supplements; D004311:Double-Blind Method; D005260:Female; D005492:Folic Acid / Q000627:therapeutic use; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D017588:Hyperandrogenism / Q000209:etiology / Q000517:prevention & control*; D006973:Hypertension / Q000209:etiology / Q000517:prevention & control; D007294:Inositol / Q000737:chemistry / Q000627:therapeutic use*; D007333:Insulin Resistance; D007558:Italy; D007986:Luteinizing Hormone / Q000097:blood; D008599:Menstruation Disturbances / Q000209:etiology / Q000517:prevention & control*; D008796:Metrorrhagia / Q000209:etiology / Q000517:prevention & control; D009839:Oligomenorrhea / Q000209:etiology / Q000517:prevention & control; D010053:Ovary / Q000503:physiopathology*; D011085:Polycystic Ovary Syndrome / Q000097:blood / Q000178:diet therapy* / Q000378:metabolism / Q000503:physiopathology; D013237:Stereoisomerism; D055815:Young Adult
chemical_list: D007294:Inositol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D005492:Folic Acid